世界の再発性多形性膠芽腫(GBM)治療市場規模・現状・予測2021-2027

【英語タイトル】Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size, Status and Forecast 2021-2027

QYResearchが出版した調査資料(QY21APR4963)・商品コード:QY21APR4963
・発行会社(調査会社):QYResearch
・発行日:2021年4月(※2024年版があります。お問い合わせください)
・ページ数:91
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査資料では、再発性多形性膠芽腫(GBM)治療の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(経口薬、テモゾロミド、放射線増感剤、ニトロソウレア薬、放射線療法、化学療法)、用途別市場規模(病院、診療所、外来手術センター)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・再発性多形性膠芽腫(GBM)治療の市場動向
・企業の競争状況、市場シェア
・再発性多形性膠芽腫(GBM)治療の種類別市場規模(経口薬、テモゾロミド、放射線増感剤、ニトロソウレア薬、放射線療法、化学療法)
・再発性多形性膠芽腫(GBM)治療の用途別市場規模(病院、診療所、外来手術センター)
・再発性多形性膠芽腫(GBM)治療の北米市場規模2016-2027(アメリカ、カナダ)
・再発性多形性膠芽腫(GBM)治療の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・再発性多形性膠芽腫(GBM)治療のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・再発性多形性膠芽腫(GBM)治療の中南米市場規模2016-2027(メキシコ、ブラジル)
・再発性多形性膠芽腫(GBM)治療の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Astrazeneca、Roche、GlaxoSmithKline、Merck、Pfizer、AngioChem、Vascular Biogeneics)
・結論
【レポートの概要】

Recurrent glioblastoma multiforme is the most aggressive cancer that begins within the brain.
The increasing incidence of seizure is expected to drive the recurrent glioblastoma multiforme treatment market.

Market Analysis and Insights: Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market
The global Recurrent Glioblastoma Multiforme (GBM) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Recurrent Glioblastoma Multiforme (GBM) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Recurrent Glioblastoma Multiforme (GBM) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Recurrent Glioblastoma Multiforme (GBM) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Recurrent Glioblastoma Multiforme (GBM) Treatment market.

Global Recurrent Glioblastoma Multiforme (GBM) Treatment Scope and Market Size
Recurrent Glioblastoma Multiforme (GBM) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recurrent Glioblastoma Multiforme (GBM) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Oral Medications
Temozolomide
Radiosensitizers
Nitrosoureas Drugs
Radiation Therapy
Chemotherapy

Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Astrazeneca
Roche
GlaxoSmithKline
Merck
Pfizer
AngioChem
Vascular Biogeneics

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oral Medications
1.2.3 Temozolomide
1.2.4 Radiosensitizers
1.2.5 Nitrosoureas Drugs
1.2.6 Radiation Therapy
1.2.7 Chemotherapy
1.3 Market by Application
1.3.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Perspective (2016-2027)
2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Growth Trends by Regions
2.2.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Industry Dynamic
2.3.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Trends
2.3.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Drivers
2.3.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Challenges
2.3.4 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Revenue
3.1.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Revenue (2016-2021)
3.1.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue
3.4 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio
3.4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2020
3.5 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players Head office and Area Served
3.6 Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service
3.7 Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Recurrent Glioblastoma Multiforme (GBM) Treatment Breakdown Data by Type
4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Type (2022-2027)

5 Recurrent Glioblastoma Multiforme (GBM) Treatment Breakdown Data by Application
5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027)
6.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
6.2.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021)
6.2.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027)
6.2.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027)
6.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
6.3.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021)
6.3.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027)
6.3.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027)
6.4 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country
6.4.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021)
6.4.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027)
7.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
7.2.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027)
7.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
7.3.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027)
7.4 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country
7.4.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
8.2.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
8.3.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region
8.4.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027)
9.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
9.2.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027)
9.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
9.3.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027)
9.4 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country
9.4.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
10.2.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
10.3.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country
10.4.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Astrazeneca
11.1.1 Astrazeneca Company Details
11.1.2 Astrazeneca Business Overview
11.1.3 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.1.4 Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.1.5 Astrazeneca Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.2.4 Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.2.5 Roche Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.3.4 GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.3.5 GlaxoSmithKline Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.4.4 Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.4.5 Merck Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.5.4 Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.5.5 Pfizer Recent Development
11.6 AngioChem
11.6.1 AngioChem Company Details
11.6.2 AngioChem Business Overview
11.6.3 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.6.4 AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.6.5 AngioChem Recent Development
11.7 Vascular Biogeneics
11.7.1 Vascular Biogeneics Company Details
11.7.2 Vascular Biogeneics Business Overview
11.7.3 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.7.4 Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.7.5 Vascular Biogeneics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Oral Medications
Table 3. Key Players of Temozolomide
Table 4. Key Players of Radiosensitizers
Table 5. Key Players of Nitrosoureas Drugs
Table 6. Key Players of Radiation Therapy
Table 7. Key Players of Chemotherapy
Table 8. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2016-2021)
Table 12. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2022-2027)
Table 14. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Trends
Table 15. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Drivers
Table 16. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Challenges
Table 17. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Restraints
Table 18. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Players (2016-2021)
Table 20. Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment as of 2020)
Table 21. Ranking of Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service
Table 25. Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2016-2021)
Table 29. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Application (2016-2021)
Table 33. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 65. Astrazeneca Company Details
Table 66. Astrazeneca Business Overview
Table 67. Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 68. Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 69. Astrazeneca Recent Development
Table 70. Roche Company Details
Table 71. Roche Business Overview
Table 72. Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 73. Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 74. Roche Recent Development
Table 75. GlaxoSmithKline Company Details
Table 76. GlaxoSmithKline Business Overview
Table 77. GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 78. GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 79. GlaxoSmithKline Recent Development
Table 80. Merck Company Details
Table 81. Merck Business Overview
Table 82. Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 83. Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 84. Merck Recent Development
Table 85. Pfizer Company Details
Table 86. Pfizer Business Overview
Table 87. Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 88. Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 89. Pfizer Recent Development
Table 90. AngioChem Company Details
Table 91. AngioChem Business Overview
Table 92. AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 93. AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 94. AngioChem Recent Development
Table 95. Vascular Biogeneics Company Details
Table 96. Vascular Biogeneics Business Overview
Table 97. Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 98. Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 99. Vascular Biogeneics Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Oral Medications Features
Figure 3. Temozolomide Features
Figure 4. Radiosensitizers Features
Figure 5. Nitrosoureas Drugs Features
Figure 6. Radiation Therapy Features
Figure 7. Chemotherapy Features
Figure 8. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application: 2020 VS 2027
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Ambulatory Surgical Centers Case Studies
Figure 12. Recurrent Glioblastoma Multiforme (GBM) Treatment Report Years Considered
Figure 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions: 2020 VS 2027
Figure 16. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2022-2027)
Figure 17. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Players in 2020
Figure 18. Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2020
Figure 20. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2016-2021)
Figure 21. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2022-2027)
Figure 22. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027)
Figure 24. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027)
Figure 25. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Country (2016-2027)
Figure 26. United States Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027)
Figure 30. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027)
Figure 31. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Country (2016-2027)
Figure 32. Germany Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Region (2016-2027)
Figure 42. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027)
Figure 50. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027)
Figure 51. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Country (2016-2027)
Figure 52. Mexico Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Country (2016-2027)
Figure 58. Turkey Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Astrazeneca Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 62. Roche Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 63. GlaxoSmithKline Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 64. Merck Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 65. Pfizer Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 66. AngioChem Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 67. Vascular Biogeneics Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed


【掲載企業】

Astrazeneca、Roche、GlaxoSmithKline、Merck、Pfizer、AngioChem、Vascular Biogeneics

★調査レポート[世界の再発性多形性膠芽腫(GBM)治療市場規模・現状・予測2021-2027] (コード:QY21APR4963)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の再発性多形性膠芽腫(GBM)治療市場規模・現状・予測2021-2027]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆